logo

For the Inventor, By the Inventor

Shanghai, China

Shanghai Hengrui Pharmaceutical Co., Ltd.


USPTO Granted Patents = 100



Forward Citations = 142

Loading Chart...
Loading Chart...

199 inventors (with patents filed for the assignee):

goldMedal Weikang Tao (44 out of 49 patents)

silverMedal Piaoyang Sun (25 out of 42 patents)

bronzeMedal Feng He (24 out of 79 patents)

4.  Lianshan Zhang (22 out of 29 patents)

5.  Qiyue Hu (18 out of 20 patents)

6.  Qing Dong (15 out of 67 patents)

7.  Fanglong Yang (15 out of 20 patents)

8.  Peng Cho Tang (14 out of 21 patents)

9.  Guoqing Cao (10 out of 15 patents)

10.  Lei Zhang (9 out of 138 patents)

11.  Fei Li (9 out of 56 patents)

12.  Xiangdong Qu (8 out of 8 patents)

13.  Xin Ye (8 out of 14 patents)

14.  Hu Ge (7 out of 8 patents)

15.  Dongbing Cui (7 out of 7 patents)


Core Competencies:
Anti-PD-1 Antibody
VEGFR Inhibitor
Tricyclic Tetrahydroisoquinoline
Fused Pyridine Ring Derivative
Anti-Claudin 18.2 Antibody
IL-5 Antibody
Benzimidazole Derivatives
CD3 Antibody
PD-L1 Antibody
TIGIT Antibody
Interleukin 15 Protein Complex
Pyrazolo-Heteroaryl Derivative

100 patents:

1. 12435144 - Use of combination of anti-PD-1 antibody and VEGFR inhibitor in preparation of drug for treating cancers (2025-10-07),
2. 12428482 - Anti-PD-1 antibody, antigen-binding fragment thereof and pharmaceutical use thereof (2025-09-30),
3. 12428478 - Anti-Claudin 18.2 antibody and application thereof (2025-09-30),
4. 12428428 - Tricyclic tetrahydroisoquinoline derivative, preparation method therefor and application thereof in medicine (2025-09-30),
5. 12428396 - Fused pyridine ring derivative, preparation method therefor, and pharmaceutical use thereof (2025-09-30),
6. 12404323 - Antibody capable of binding to thymic stromal lymphopoietin and use thereof (2025-09-02),
7. 12325741 - Anti-Aβ antibodies and antigen-binding fragments thereof (2025-06-10),
8. 12325696 - Indazole derivative, preparation method therefor, and pharmaceutical application thereof (2025-06-10),
9. 12269823 - Crystal form of pyridopyrimidine derivative and preparation method thereof (2025-04-08),
10. 12258405 - CD3 antibody and pharmaceutical use thereof (2025-03-25),
11. 12258394 - IL-5 antibody, antigen binding fragment thereof, and medical application therefor (2025-03-25),
12. 12202891 - Antibody capable of binding to thymic stromal lymphopoietin and use thereof (2025-01-21),
13. 12187684 - Benzimidazole derivatives as modulators of retinoid-related orphan receptor gamma (RORγ) and pharmaceutical use thereof (2025-01-07),
14. 12162944 - Human IL-4R binding antibody, antigen binding fragment thereof, and medical use thereof (2024-12-10),
15. 12162879 - Pyridopyrimidine derivative, preparation method therefor and medical use thereof (2024-12-10),
Shanghai Hengrui Pharmaceutical Co., Ltd. is a leading Chinese pharmaceutical company dedicated to the research, development, manufacturing, and commercialization of innovative drugs. With more than 40 years of experience, the company focuses on areas such as oncology, cardiovascular diseases, metabolic disorders, and more. Hengrui Pharma is committed to improving the quality of life for patients worldwide through its high-quality and affordable pharmaceutical products.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 16 2025

100 Patents

#35 in Shanghai

#307 in China

#7,553 in the World

...
Shanghai, China

Shanghai Hengrui Pharmaceutical Co., Ltd.

Forward Citations = 142

199 inventors:

goldMedal Weikang Tao (44 out of 49 patents)

silverMedal Piaoyang Sun (25 out of 42 patents)

bronzeMedal Feng He (24 out of 79 patents)

4.  Lianshan Zhang (22 out of 29 patents)

5.  Qiyue Hu (18 out of 20 patents)

Please report any incorrect information to support@idiyas.com
Loading…